Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
Key Points Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better. Compass Pathways…
Compass Pathways Clears Another Hurdle – Builds Stronger FDA Case For Its Much-Awaited Depression Therapy
Among patients receiving a 25 mg dose, 39% achieved a clinically meaningful reduction in depression symptoms by Week…
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically…